NR3C2 and heart failure: The cardiovascular endpoint trials RALES (Randomized ALdactone Evaluation Study) [8] and EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) [9] conducted in patients with HFrEF, as well as ALDO-DHF (Aldosterone Receptor Blockade in Diastolic Heart Failure) [10] and TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) [11] conducted in patients with HFpEF, have demonstrated the beneficial effects of eplerenone or spironolactone on morbidity and mortality.